BIOS Capital Management, LP
In its 13F for Q4 2025 (holdings as of December 31, 2025, filed February 13, 2026), BIOS Capital Management, LP reported 6 stock positions worth $82.6 million. Its top holding was Actuate Therapeutics (ACTU) at 74.4% of the portfolio, followed by Cognition Therapeutics (CGTX, 9.8%) and Opus Genetics (IRD, 9.0%). Compared with Q3 2025, it opened 1 new position, sold out of 1 and reduced 1. The biggest buy was a new position in IN8BIO (INAB) and the biggest sale Lantern Pharma (LTRN, shares −1%).
- Most Recent 13F
- Q2 2026
- Location
- Fort Worth, TX
- CIK
- 0001813845
- Portfolio Value
- $82.6M (Q4 2025)
- SEC Filing
- 0001813845-26-000002 ↗ filed Feb 13, 2026
Holdings Value
Holdings 6 stocks · $82.6M
| ACTU Actuate Therapeutics Inc. | 74.44% | 10,049,996 | $61.5M | No change |
| CGTX Cognition Therapeutics Inc. | 9.80% | 6,000,000 | $8.1M | No change |
| IRD Opus Genetics Inc. | 8.96% | 3,683,429 | $7.4M | No change |
| LTRN Lantern Pharma Inc. | 3.70% | 1,009,507 | $3.1M | Reduce -0.6% |
| RNTX Rein Therapeutics Inc. | 2.37% | 1,690,751 | $2.0M | No change |
| INAB IN8BIO Inc. | 0.72% | 253,417 | $593K | New |
Portfolio Sells Q3 2025 → Q4 2025
Portfolio Buys Q3 2025 → Q4 2025
| INAB IN8BIO Inc. | New | 0.72% | +0.72 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 6 | $41.7M | ACTU, IRD, CGTX, RNTX, LTRN |
| Q1 2026 | 6 | $52.9M | ACTU, IRD, CGTX, RNTX, LTRN |
| Q4 2025 | 6 | $82.6M | ACTU, CGTX, IRD, LTRN, RNTX |
| Q3 2025 | 6 | $88.9M | ACTU, CGTX, IRD, LTRN, RNTX |
| Q2 2025 | 6 | $72.6M | ACTU, IRD, LTRN, RNTX, CGTX |
| Q1 2025 | 6 | $79.2M | ACTU, LTRN, RNTX, CGTX, INAB |
| Q4 2024Amended | 6 | $94.1M | ACTU, CGTX, RNTX, LTRN, INAB |